Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Researchers Develop Key Brake For Immune Cells In Petri Dish -- Hope For Easier Organ Transplantation?
Scientists from the Helmholtz Center for Infection Research in Braunschweig, Germany and the Medical School Hannover, Germany have succeeded in treating immune cells in a way that enables them to inhibit unwanted immune reactions such as organ rejection. Their results have now been published in the current issue of the scientific journal Journal of Cellular and Molecular Medicine.
generic viagra online
Obama Says Lawmakers Should Not Become Sidetracked By Abortion Debate In Health Reform
In an interview with CBS" "Evening News" on Tuesday, President Obama said that lawmakers should "not get distracted by the abortion debate" as they weigh health reform legislation. When asked by "Evening News" anchor Katie Couric if he would "favor a government option that would cover abortions," Obama replied that what he thinks is "important, at this stage, is not trying to micro-manage what benefits are covered." He added that his "main focus is making sure that people have the options of high-quality care at the lowest possible price." Obama also said, "As you know, I"m pro-choice. But I think we also have the tradition of, in this town, historically, of not financing abortions as part of government-funded health care." He continued that "[r]ather than wade into that issue at this point, I think it"s appropriate for us to figure out how to just deliver on the cost savings, and not get distracted by the abortion debate at this station" (Couric, "Evening News," CBS, 7/21).
News of the day
GOP Ramps Up Attacks
"Emboldened by divided Democrats and polls that show rising public anxiety about President Obama"s handling of health care and the economy, Republicans on Monday launched an aggressive effort to link the two, comparing the health-care bills moving through Congress to what they labeled as a failed economic stimulus bill," The Washington Post reports. "And the news Monday that the Obama administration would delay release of a congressionally mandated report on the nation"s economic conditions only stoked the rhetoric, spawning GOP speculation that the White House is trying to avoid bad news amid the health-care debate. "The last time the president made grand promises and demanded passage of a bill before it could be reviewed, we ended up with the colossal stimulus failure and unemployment near 10 percent," Sen. Jim DeMint (R-S.C.) said. "Now the president wants Americans to trust him again, but he can"t back up the utopian promises he"s making.""
Oncology

Avecia Launches Toolkit For Production Of Antibody Fragments

Avecia Biologics has announced it has created a "toolkit" of technologies to meet the production challenges for the next generation of antibody-based therapeutics. The toolkit consists of four elements, bringing together Avecia"s high yield microbial expression system - pAVEway™ - with innovative downstream technologies for purification, refold and PEGylation. Using Avecia"s expertise in these areas, the company offers its clients rapid process development, combined with tested and well understood platforms applicable to a wide range of antibody fragment types and alternative scaffolds. The first element of the "toolkit" is Avecia"s award-winning pAVEway™ technology, comprising innovative vectors, selected host strains and highly optimised production systems, giving rapid and efficient antibody fragment expression and scale up. Purification technology forms the second part of the package, with Avecia"s recent development of two complementary purification technologies for use with antibody fragments produced in microbial systems. The first - a universal platform - offers optimised screening for rapid selection and has been demonstrated on a range of antibody fragments. The second is an affinity platform, and has high selectivity for antibody fragments, even at low concentration. The third element of the "toolkit" is a Refold platform, where Avecia has developed a rapid optimisation procedure for protein refolding. The company"s experience includes the successful use of refolding in the clinical manufacture of over 25 different products. The final part of the offering is PEGylation technology. PEGylation is the method of choice for improving the pharmacokinetic properties and immunogenicity profiles of proteins, including antibody fragments. Avecia has a track record of success with maleimide PEGylyation and is now also collaborating with PolyTherics, a company specialising in precision engineering of protein half-life, to apply its proprietary technologies to antibody fragments. Dr Mark Carver, Chief Scientific Officer at Avecia Biologics, said: "Packaging our capabilities for antibody fragment production together in this way will enable our customers to choose the elements most applicable to the development of their molecule. We are committed to being at the forefront of technologies which will help deliver robust and reliable production processes rapidly to our clients, thereby reducing their time to clinic". Avecia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009